Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (GILD), Climb Bio (CLYM) and Legend Biotech (LEGN)
at www.tipranks.com (Mon, 9-Nov 9:00 PM)
Climb Bio’s Buy Rating Reiterated as Pipeline Catalysts Advance; Price Target Unchanged at $30
at www.tipranks.com (Mon, 9-Nov 7:16 AM)
Climb Bio spotlights 12-week APRIL suppression and ~70% Gd-IgA1 reduction in new CLYM116/MIL116 Phase 1 update
Market Chameleon (Mon, 26-Oct 11:20 AM)
